Aurinia Pharmaceuticals Company Profile (NASDAQ:AUPH)

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AUPH
  • CUSIP:
Key Metrics:
  • Previous Close: $2.17
  • 50 Day Moving Average: $3.11
  • 200 Day Moving Average: $2.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.56
  • P/E Growth: 0.00
  • Market Cap: $76.57M
  • Outstanding Shares: 35,286,000
  • Beta: 3.09
Additional Links:
Companies Related to Aurinia Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (314.75% upside)

Analysts' Ratings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Show:
DateFirmActionRatingPrice TargetDetails
8/17/2016HC WainwrightBoost Price TargetBuy$7.00 -> $10.00View Rating Details
8/16/2016Leerink SwannReiterated RatingOutperformView Rating Details
8/15/2016FBR & CoReiterated RatingOutperform$9.00View Rating Details
8/5/2016Canaccord GenuitySet Price TargetBuy$10.00View Rating Details
5/8/2015MLV & Co.Initiated CoverageBuy$9.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/31/2015($0.11)($0.15)ViewN/AView Earnings Details
11/12/2014Q3 14($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.14)($0.14)($0.14)
Q2 20161($0.15)($0.15)($0.15)
Q3 20162($0.15)($0.12)($0.14)
Q4 20162($0.13)($0.12)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Aurinia Pharmaceuticals (NASDAQ:AUPH)
DateHeadline
investornewswire.com logoAurinia Pharmaceuticals Inc (NASDAQ:AUPH) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:AUPH)
www.investornewswire.com - August 22 at 8:45 PM
News IconInvestor's Alert: Aurinia Pharmaceuticals (AUPH), Alimera Sciences (ALIM) - Newburg Press (NASDAQ:AUPH)
newburghpress.com - August 19 at 4:16 PM
News IconAurinia Pharmaceuticals Inc.'s (AUPH): Stock Analysis Review - Hot Stocks Point (NASDAQ:AUPH)
www.hotstockspoint.com - August 18 at 3:49 PM
streetinsider.com logoFBR See Sell Off in Aurinia Pharma (AUPH) as Overdone; Remains Positive on Voclosporin (NASDAQ:AUPH)
www.streetinsider.com - August 17 at 11:51 AM
investornewswire.com logoWill Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Hit $9 Price Target? - Investor Newswire (NASDAQ:AUPH)
www.investornewswire.com - August 16 at 3:42 PM
News IconAurinia Pharmaceuticals (NASDAQ:AUPH) & Avis Budget Group Inc. (NASDAQ:CAR) Active Movers - Money News (press release) (NASDAQ:AUPH)
www.newsismoney.com - August 16 at 3:42 PM
News IconPatient deaths distract the Street from Aurinia promising lupus data (NASDAQ:AUPH)
www.bioworld.com - August 15 at 9:11 PM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Up 2.7%; Providence & Worcester Railroad Shares Spike Higher (NASDAQ:AUPH)
www.benzinga.com - August 15 at 3:44 PM
nasdaq.com logoMid-Day Market Update: Sorl Auto Parts Gains Following Q2 Results; Performance Sports Shares Slide (NASDAQ:AUPH)
www.nasdaq.com - August 15 at 3:44 PM
stockhouse.com logoMid-Morning Market Update: Markets Open Higher; SYSCO Profit Tops Estimates (NASDAQ:AUPH)
www.stockhouse.com - August 15 at 10:52 AM
4-traders.com logoAurinia Pharmaceuticals : Announces Voclosporin Meets Primary Endpoint (NASDAQ:AUPH)
www.4-traders.com - August 15 at 10:52 AM
News IconAurinia Pharmaceuticals Inc (NASDAQ:AUPH): Our Subscribers Are Already Up A W Whopping 45% In Just 3-Sessuion After Buy Call (NASDAQ:AUPH)
www.marketnewscall.com - August 15 at 10:52 AM
News IconAurinia Pharmaceuticals (AUPH) Plunges Despite Upbeat Trial Data (NASDAQ:AUPH)
www.economiccalendar.com - August 15 at 10:52 AM
News IconAurinia Pharmaceuticals Inc (NASDAQ:AUPH): We Bought The Stock At $3.24, Now Up Crazy 40% Quickly (NASDAQ:AUPH)
www.marketnewscall.com - August 11 at 9:32 PM
News IconAurinia Pharmaceuticals Inc (NASDAQ:AUPH): That’s How Our Members Made 40% In No Time, Join Us (NASDAQ:AUPH)
www.marketnewscall.com - August 11 at 12:54 PM
streetinsider.com logoForm 6-K Aurinia Pharmaceuticals For: Jun 30 (NASDAQ:AUPH)
www.streetinsider.com - August 5 at 3:40 PM
finance.yahoo.com logoAurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York (NASDAQ:AUPH)
finance.yahoo.com - July 28 at 7:56 PM
finance.yahoo.com logoAurinia Announces Appointment of Head of Communications & Advocacy (NASDAQ:AUPH)
finance.yahoo.com - July 11 at 10:50 AM
seekingalpha.com logoAurinia Pharmaceuticals: Looking Even Better (NASDAQ:AUPH)
seekingalpha.com - July 5 at 8:26 AM
breakingfinancenews.com logoAurinia Pharmaceuticals Inc (NASDAQ:AUPH) stock price target bumped up to $7 as covered today by H.C. Wainwright (NASDAQ:AUPH)
breakingfinancenews.com - July 1 at 11:42 AM
finance.yahoo.com logoCoverage initiated on Aurinia Pharma by H.C. Wainwright (NASDAQ:AUPH)
finance.yahoo.com - June 30 at 7:16 AM
4-traders.com logoAurinia Pharmaceuticals : Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) (NASDAQ:AUPH)
www.4-traders.com - June 29 at 11:52 AM
finance.yahoo.com logoAurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) (NASDAQ:AUPH)
finance.yahoo.com - June 28 at 6:45 PM
baystreet.ca logoAurinia Pharmaceuticals Inc. (AUPH) Down on Private Placement (NASDAQ:AUPH)
www.baystreet.ca - June 23 at 5:09 PM
finance.yahoo.com logoAurinia Announces Closing of US$7 Million Private Placement (NASDAQ:AUPH)
finance.yahoo.com - June 22 at 5:15 PM
fxpips.com logoMost Active Stocks on Retreat – AUPH, NVLS, GBT, BOBE, CRAY, SALT (NASDAQ:AUPH)
www.fxpips.com - June 16 at 8:03 AM
nasdaq.com logoMid-Day Market Update: Patriot National Climbs Following Offer from Ebix; Carbylan Therapeutics Shares Tumble (NASDAQ:AUPH)
www.nasdaq.com - June 15 at 3:44 PM
benzinga.com logoMid-Morning Market Update: Markets Open Higher; Aegerion Pharmaceuticals And QLT Agree To Merge (NASDAQ:AUPH)
www.benzinga.com - June 15 at 3:44 PM
investors.com logoAurinia Pharmaceuticals raises US$7mln for lupus drug development (NASDAQ:AUPH)
www.proactiveinvestors.com - June 15 at 3:44 PM
finance.yahoo.com logoAurinia Announces Results of Annual General Meeting (NASDAQ:AUPH)
finance.yahoo.com - June 9 at 7:29 PM
capitalcube.com logoAurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 (NASDAQ:AUPH)
www.capitalcube.com - June 1 at 12:27 PM
finance.yahoo.com logoAurinia to Host Conference Call & Webcast to Review Results from the AURION Study (NASDAQ:AUPH)
finance.yahoo.com - February 11 at 1:47 PM
News IconAurinia Pharmaceuticals Inc (AUPH) Shares Jump 19.5% on Positive Phase 2 Results for Voclosporin - Independent Reporter (NASDAQ:AUPH)
ir.net - February 8 at 3:02 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Issues Positive Update on AURION Study in Lupus Nephritis (NASDAQ:AUPH)
www.streetinsider.com - February 8 at 3:02 PM
finance.yahoo.com logoAurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis (NASDAQ:AUPH)
finance.yahoo.com - February 8 at 8:30 AM
News IconAurinia Pharmaceuticals Ord (NASDAQ:AUPH) Short Interest Increased By 8.14% - fdanewsalert.com (NASDAQ:AUPH)
www.fdanewsalert.com - February 7 at 2:05 PM
finance.yahoo.com logoAurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences (NASDAQ:AUPH)
finance.yahoo.com - February 4 at 4:30 PM
finance.yahoo.com logoAurinia Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference (NASDAQ:AUPH)
finance.yahoo.com - February 2 at 4:43 PM
investornewswire.com logoSentiment And Earnings Update For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Investor Newswire (NASDAQ:AUPH)
www.investornewswire.com - February 2 at 2:11 PM
finance.yahoo.com logoAurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day (NASDAQ:AUPH)
finance.yahoo.com - January 29 at 6:53 PM
investornewswire.com logoAnalysts Issue Earnings Forecast For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Investor Newswire (NASDAQ:AUPH)
www.investornewswire.com - January 21 at 1:06 PM
finance.yahoo.com logo5:20 pm Aurinia Pharma completes patient enrollment in its phase 2B AURA-LV study in Lupus Nephritis (NASDAQ:AUPH)
finance.yahoo.com - January 19 at 5:20 PM
finance.yahoo.com logoAurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis (NASDAQ:AUPH)
finance.yahoo.com - January 19 at 5:17 PM
capitalcube.com logoAurinia Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:AUPH)
www.capitalcube.com - December 18 at 9:48 AM
finance.yahoo.com logoDermira (DERM) Looks Good: Stock Adds 5.9% in Session (NASDAQ:AUPH)
finance.yahoo.com - December 15 at 8:25 AM
finance.yahoo.com logoAURINIA PHARMACEUTICALS INC. Financials (NASDAQ:AUPH)
finance.yahoo.com - December 8 at 1:11 PM
finance.yahoo.com logoIgnyta (RXDX) Looks Good: Stock Jumps 7.1% in Session (NASDAQ:AUPH)
finance.yahoo.com - November 24 at 8:35 AM
finance.yahoo.com logoAurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned (NASDAQ:AUPH)
finance.yahoo.com - November 24 at 8:30 AM
sg.finance.yahoo.com logoAurinia reports 3Q loss (NASDAQ:AUPH)
sg.finance.yahoo.com - November 13 at 4:32 PM
finance.yahoo.com logoAurinia Reports Third Quarter 2015 Financial Results (NASDAQ:AUPH)
finance.yahoo.com - November 13 at 4:15 PM

Social

Aurinia Pharmaceuticals (NASDAQ:AUPH) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff